Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement
The Indian Journal of Medical Research · 2025
DOI: 10.25259/ijmr_2009_2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Indian Journal of Medical Research, 2025. Verfasst von Neeraj Arora und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, & Molecular Genetics, Unipath Specialty Laboratory, Ahmedabad, Gujarat, India. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Results from a recent Phase 3 clinical trial (DESTINY-Breast04) established the efficacy of the antibody-drug conjugate, trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer with immunohistochemistry (IHC) score 1+ or 2+ and without in situ hybridization amplification, defining a new category of metastatic breast cancer known as human epidermal growth factor receptor 2 (HER2)-low. Across studies of patients with primary or metastatic breast cancer, approximately 50 per cent have HER2-low tumours, thereby emphasizing the importance of accurately identifying these tumours. Results from the DESTINY-Breast06 trial further corroborated the DESTINY-Breast04 results showing T-DXd as a new standard of care for patients with HER2-low and HER2-ultralow (defined as IHC score 0 with membrane staining) metastatic breast cancer following one or more lines of hormone therapy. Differentiating between HER2 IHC scores 0 and 1+ shows significant interobserver variability, possibly because the low scores did not have any clinical relevance until now. To establish a standardized approach in scoring of HER2-low tumours in India, a panel of experts comprising histopathologists, molecular pathologists, and clinicians met to discuss guidelines on HER2 testing. The identification of HER2-low expression depends on multiple methodological pre-analytical and analytical variables, including sample handling, fixation, processing, antigen clones, staining methodology, and substrates. The panel also focused on the challenges in the interpretation of HER2-low status. Challenges in the pre-analytical and analytical phases could be addressed by rigorous quality control procedures and training the pathologists. In the post-analytical phase, the subjective mode of HER2 assessment and HER2 intratumoural heterogeneity in HER2-low breast cancer are factors that influence HER2-low assessment. The panel recommended robust standard operating procedures to overcome these challenges. The central point of discussion was to implement clear guidelines, careful supervision of pre-analytical and analytical issues, and specialized training for accurate HER2 testing that would help select patients eligible for novel therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, & Molecular Genetics, Unipath Specialty Laboratory, Ahmedabad, Gujarat, India.
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.
- Department of Histopathology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
- Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
- Department of Genomics, Ampath, Hyderabad, Telangana, India.
- Department of Hematology and Molecular Pathology, Tata Medical Center, Kolkata, West Bengal, India.
Zitieren
APA
Arora, N., Bajpai, J., Bal, A., Batra, A., Gupta, A., Mishra, D. K., Mukherjee, G., Pai, T., Parihar, M., Okaly, G. V. P., Prabhudesai, S., Shah, M., & S P, S. (2025). Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement. The Indian Journal of Medical Research. https://doi.org/10.25259/ijmr_2009_2024
Vancouver
Arora N, Bajpai J, Bal A, Batra A, Gupta A, Mishra DK, et al. Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement. The Indian Journal of Medical Research. 2025. doi:10.25259/ijmr_2009_2024
BibTeX
@article{Arora2025,
author = {Arora, Neeraj and Bajpai, Jyoti and Bal, Amanjit and Batra, Atul and Gupta, Anurag and Mishra, Deepak Kumar and Mukherjee, Geetashree and Pai, Trupti and Parihar, Mayur and Okaly, Geeta V Patil and Prabhudesai, Shilpa and Shah, Milap and S P, Somashekhar},
title = {Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement},
journal = {The Indian Journal of Medical Research},
year = {2025},
doi = {10.25259/ijmr_2009_2024}
}
EUVIMED